- Home
- STHO vs ARMP Comparison
STHO vs ARMP Comparison
Compare STHO & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STHO
- ARMP
- Stock Information
- Founded
- STHO N/A
- ARMP N/A
- Country
- STHO United States
- ARMP United States
- Employees
- STHO N/A
- ARMP N/A
- Industry
- STHO Real Estate
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STHO Real Estate
- ARMP Health Care
- Exchange
- STHO Nasdaq
- ARMP Nasdaq
- Market Cap
- STHO 113.4M
- ARMP 92.4M
- IPO Year
- STHO N/A
- ARMP N/A
- Fundamental
- Price
- STHO $8.96
- ARMP $2.92
- Analyst Decision
- STHO
- ARMP Strong Buy
- Analyst Count
- STHO 0
- ARMP 1
- Target Price
- STHO N/A
- ARMP $9.00
- AVG Volume (30 Days)
- STHO 43.4K
- ARMP 12.1K
- Earning Date
- STHO 11-04-2025
- ARMP 11-12-2025
- Dividend Yield
- STHO N/A
- ARMP N/A
- EPS Growth
- STHO N/A
- ARMP N/A
- EPS
- STHO N/A
- ARMP N/A
- Revenue
- STHO $113,989,000.00
- ARMP $6,868,000.00
- Revenue This Year
- STHO N/A
- ARMP $8.43
- Revenue Next Year
- STHO N/A
- ARMP N/A
- P/E Ratio
- STHO N/A
- ARMP N/A
- Revenue Growth
- STHO N/A
- ARMP 84.67
- 52 Week Low
- STHO $6.06
- ARMP $0.90
- 52 Week High
- STHO $14.50
- ARMP $3.14
- Technical
- Relative Strength Index (RSI)
- STHO 69.92
- ARMP 59.23
- Support Level
- STHO $8.71
- ARMP $2.79
- Resistance Level
- STHO $9.09
- ARMP $3.02
- Average True Range (ATR)
- STHO 0.22
- ARMP 0.16
- MACD
- STHO 0.01
- ARMP 0.01
- Stochastic Oscillator
- STHO 83.22
- ARMP 69.59
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties and land and development properties.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.